VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

VERAXA Biotech announced its implementation of FDA-aligned New Approach Methodologies (NAMs) across its preclinical R&D programs to accelerate its BiTAC oncology pipeline while significantly reducing animal testing. The company presented data showing its BiTAC-TCE candidates demonstrated superior safety profiles and matched efficacy compared to traditional T cell engagers, with ex vivo studies using patient-derived xenograft models requiring only 10 mice versus 200+ for traditional studies.